Home » Stocks » CHRS

Coherus BioSciences, Inc. (CHRS)

Stock Price: $18.46 USD -0.16 (-0.86%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $18.46 +0.00 (0.01%) Nov 30, 5:13 PM

Stock Price Chart

Key Info

Market Cap 1.33B
Revenue (ttm) 489.26M
Net Income (ttm) 161.76M
Shares Out 72.05M
EPS (ttm) 2.05
PE Ratio 9.00
Forward PE 12.85
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $18.46
Previous Close $18.62
Change ($) -0.16
Change (%) -0.86%
Day's Open 18.53
Day's Range 18.16 - 18.77
Day's Volume 574,207
52-Week Range 11.67 - 22.53

More Stats

Market Cap 1.33B
Enterprise Value 1.24B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 72.05M
Float n/a
EPS (basic) 2.28
EPS (diluted) 2.05
FCF / Share 1.85
Dividend n/a
Dividend Yield n/a
Earnings Yield 11.11%
FCF Yield 9.94%
Payout Ratio n/a
Shares Short 15.76M
Short Ratio 17.26
Short % of Float n/a
Beta 1.69
PE Ratio 9.00
Forward PE 12.85
P/FCF Ratio 10.06
PS Ratio 2.72
PB Ratio 5.09
Revenue 489.26M
Operating Income 184.93M
Net Income 161.76M
Free Cash Flow 132.23M
Net Cash 89.67M
Net Cash / Share 1.24
Gross Margin 50.06%
Operating Margin 37.80%
Profit Margin 33.10%
FCF Margin 27.03%
ROA 20.45%
ROE 103.78%
ROIC 33.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 8
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$29.90*
(61.97% upside)
Low
19.0
Current: $18.46
High
35.0
Target: 29.90
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue356-1.5619030.0431.112.751.90
Revenue Growth---99.18%532.82%-3.42%1030.72%44.87%-
Gross Profit339-1.5619030.0431.112.751.90
Operating Income108-204-232-116-219-64.68-35.99-38.52
Net Income89.83-209-238-127-223-87.13-53.64-33.02
Shares Outstanding69.6865.0353.1341.9137.128.193.332.08
Earnings Per Share1.23-3.22-4.48-3.04-6.01-10.64-16.10-15.85
Operating Cash Flow28.36-159-200-253-108-23.9315.42-18.25
Capital Expenditures-1.82-0.79-4.57-6.52-6.16-2.85-0.37-1.78
Free Cash Flow26.53-160-205-259-114-26.7815.05-20.03
Cash & Equivalents17872.4112712515815239.71-
Total Debt189103102100--4.20-
Net Cash / Debt-10.97-30.6925.3624.7515815235.51-
Assets40999.4716317821218747.45-
Liabilities30413813215921912089.83-
Book Value105-38.5931.8220.53-6.2166.80-97.08-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Coherus BioSciences, Inc.
Country United States
Employees 306
CEO Denny M. Lanfear

Stock Information

Ticker Symbol CHRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CHRS
IPO Date November 6, 2014

Description

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Company; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.